Forty-Fifth Annual General Meeting of Ajanta Pharma on 18th July 2024 

Ajanta Pharma Limited has announced that its Forty-Fifth Annual General Meeting (AGM) will be held on Thursday, 18th July 2024, at 11:00 a.m. IST. The meeting will be conducted through Video Conferencing (VC) or Other Audio-Visual Means (OAVM) in light of current circumstances.

The AGM will cover important agenda items including:

Ordinary Business:

1. Adoption of Financial Statements:
   • Audited Standalone Financial Statements for the year ended 31 March 2024, along with the Directors' and Auditors' reports.
   • Audited Consolidated Financial Statements for the year ended 31 March 2024, along with the Auditors' report.
2. Confirmation of Interim Dividends:
   • Confirmation of the first interim dividend of Rs 25 per equity share and the second interim dividend of Rs 26 per equity share, totaling Rs 51 per equity share for FY 2024.
3. Re-appointment of Director:
   • Re-appointment of Mr. Mannalal B. Agrawal, who retires by rotation and offers himself for re-appointment.

Special Business:

4. Appointment of Mr. David Rasquinha as Independent Director:
   • Appointment for a term of 5 years from 02 May 2024.
5. Appointment of Ms. Medha Joshi as Independent Director:
   • Appointment for a term of 5 years from 02 May 2024.
6. Appointment of Mr. Rajesh Dalal as Independent Director:
   • Appointment for a term of 5 years from 02 May 2024.
7. Appointment of Ms. Simi Thapar as Independent Director:
   • Appointment for a term of 5 years from 02 May 2024.
8. Ratification of Remuneration for Cost Auditors:
   • Ratification of remuneration of Rs 6.50 lakh plus GST and reimbursement of actual travel and out-of-pocket expenses for M/s. RA & Co., Cost Accountants, for the financial year ending 31 March 2025.

Ajanta Pharma will also be submitting its Annual Report and Business Responsibility & Sustainability Report for the financial year 2023-24 as part of the AGM proceedings.

Ajanta Pharma Annual Report 2024 

Ajanta Pharma's latest Annual Report for 2024 highlights the company's robust performance and strategic growth in the Branded Generics business across India and over 30 emerging market countries in Asia and Africa.

This geographical diversification provides Ajanta Pharma with business stability, scalability, and sustainability, allowing the company to grow faster than the market in each of the regions it operates in.

Ajanta Pharma boasts a portfolio of over 300 products across specialty segments such as Cardiology, Antidiabetic, Ophthalmology, Dermatology, and Pain Management. Notably, more than 50% of this portfolio consists of first-to-market products. A dedicated field force of 3,000 professionals promotes these products, solidifying Ajanta Pharma's strong market position.

Expanding in Asia and Africa

In Asia and Africa, Ajanta Pharma's Branded Generics business spans eight major therapeutic segments, where the company holds leading positions in sub-therapeutic areas. With a product basket exceeding 200 items, Ajanta Pharma focuses on chronic therapies including Cardiology, Antidiabetic, Ophthalmology, Dermatology, and Pain Management.

In FY 2024, Ajanta Pharma introduced 27 new products in these regions and increased its field force to over 1,800 members. The company plans to add 200 more personnel next year to enhance market penetration through new product launches.

For more detailed insights and information, refer to Ajanta Pharma's 2024 Annual Report.

Ajanta Pharma Limited 

Ajanta Pharma is a leading specialty pharmaceutical company that provides quality medicines in over 30 countries. It excels in multiple molecules and therapeutic segments with first-to-market products.

The company operates in Branded Generics in India and Emerging Markets of Asia and Africa, Generics in the USA, and Institutional Sales in Africa, ensuring a scalable and sustainable business model.

Ajanta Pharma runs seven state-of-the-art manufacturing facilities in India, with approvals from the US FDA and WHO. Its strong R&D team, consisting of over 800 scientists, focuses on developing complex and innovative products to meet global patient needs.

With a diverse workforce of 7,900 employees from more than 30 nationalities, Ajanta Pharma is committed to serving global healthcare needs through empathy, innovation, and technology.